Roche culls development of two Huntington’s disease programmes

RG6662Negative

AI Analysis

Summary

Roche has terminated development of two Huntington's disease programs, leaving RG6662, a gene therapy candidate, as its sole remaining program in this indication.

Outcome Details

Two Huntington's disease programs terminated; one remaining candidate (RG6662) continues development

Importance:4/10

Sentiment:

-0.60

Huntington's diseaseprogram terminationgene therapypipeline update

Related Companies

$RHHBY

Read the original article

Published by Clinical Trials Arena on July 10, 2026 10:40 AM

Read Original